Aeglea BioTherapeutics

$7.41
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.54 (-6.79%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell AGLE and other stocks, options, ETFs, and crypto commission-free!

About AGLE

Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the design and development of human enzyme therapeutics for patients with rare genetic diseases and cancer. It develops pegzilarginase, its lead investigational therapy for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. Read More The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.

Employees
61
Headquarters
Austin, Texas
Founded
2013
Market Cap
214.04M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
72.33K
High Today
$7.98
Low Today
$7.31
Open Price
$7.92
Volume
62.92K
52 Week High
$11.16
52 Week Low
$5.99

Collections

AGLE Earnings

-$0.64
-$0.55
-$0.46
-$0.37
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 7, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.